Infliximab as a second‐line therapy for children with refractory Kawasaki disease: A systematic review and meta‐analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Infliximab as a second‐line therapy for children with refractory Kawasaki disease: A systematic review and meta‐analysis of randomized controlled trials

Published:2022-10-19 Issue:1 Volume:89 Page:49-60
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Kabbaha Suad¹^ORCID,Milano Alyssa¹^ORCID,Aldeyab Mamoon A.²^ORCID,Thorlund Kristian¹^ORCID

Affiliation:

1. Department of Health Research Methods, Evidence and Impact McMaster University Hamilton ON Canada

2. Department of Pharmacy, School of Applied Sciences University of Huddersfield Huddersfield UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15547

Reference33 articles.

1. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association

2. Corticosteroids for the treatment of Kawasaki disease in children

3. Epidemiology of Kawasaki Disease in Canada 2004 to 2014: Comparison of Surveillance Using Administrative Data vs Periodic Medical Record Review

4. The Treatment of Kawasaki Syndrome with Intravenous Gamma Globulin

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Activation of HIF2 leads to vascular remodeling and inflammation, coronary thrombosis and arterial dilation, recapitulating cardiac involvement of Kawasaki disease;2024-01-25

2. Hemolytic anemia associated with intravenous immunoglobulin in Kawasaki disease;BMC Pediatrics;2024-01-20

3. Prise en charge thérapeutique de la maladie de Kawasaki;Journal de Pédiatrie et de Puériculture;2023-12

4. Vasculiti facili e difficili: cosa deve sapere e saper fare un pediatra;Medico e Bambino;2023-05-27